TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved tiratricol, sold as Emcitate, to treat peripheral thyrotoxicosis in adults and children with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The approval is the first for the rare genetic disorder and was supported by two studies; the drugmaker says U.S. availability is expected within 8 to 10 weeks.
The U.S. Food and Drug Administration approved tiratricol, marketed as Emcitate, for peripheral thyrotoxicosis in adults and children with MCT8 deficiency, the agency announced Monday. It is the first FDA-approved treatment for the rare genetic disorder, which disrupts thyroid hormone transport into cells and can cause severe neurological impairment as well as strain on the heart and metabolism.
The approval covers patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. Tiratricol is a thyroid hormone receptor agonist. FDA official Hylton Joffe said the drug can enter cells without relying on the MCT8 transporter, which is impaired in people with the disorder, and that it lowers elevated blood thyroid hormone levels.
The FDA cited evidence from two studies: the randomized, placebo-controlled ReTRIACt trial, with 20 participants ages 5 to 31, and an open-label study involving 46 participants ages 10 months to 66.8 years. Across the studies, tiratricol lowered excess blood thyroid hormone levels. The source report says the studies also found improvements in cardiovascular and metabolic symptoms affected by thyroid levels, including systolic blood pressure and heart rate.
Tiratricol is taken once daily as a liquid suspension, by mouth or through a feeding tube for people who have difficulty swallowing. The most commonly reported adverse effects include diarrhea, vomiting, rash and excessive sweating. Its prescribing information includes a boxed warning that the drug is not intended for weight loss or obesity, and cautions against use in people with primary hyperthyroidism or alongside other thyroid medications.
A Treatment for Peripheral Thyrotoxicosis
MCT8 deficiency creates a difficult imbalance: impaired transport leaves the central nervous system deprived of thyroid hormone while peripheral tissues can be exposed to excess active T3. Tiratricol’s ability to enter cells without relying on the defective transporter provides an approved way to address the peripheral hormone excess. The FDA approval gives U.S. clinicians a treatment specifically indicated for that part of the disorder.
The disorder is described as rare, life-limiting and X-linked, and primarily affects males. The source report says affected people can have profound neurodevelopmental impairment, including difficulty sitting or walking independently, alongside persistent effects on the heart and metabolism. The approval addresses peripheral thyrotoxicosis; the available source material does not establish that tiratricol reverses neurological impairment or cures the underlying genetic condition.
How MCT8 Disruption Affects the Body
MCT8 is a cell-surface transporter involved in moving thyroid hormone into cells. According to the source report, mutations in the SLC16A2 gene disrupt this transporter, upsetting thyroid hormone signaling in different tissues. The resulting imbalance includes inadequate thyroid hormone signaling in the central nervous system and excessive active T3 exposure in peripheral tissues.
FDA approval followed evidence from one small randomized, placebo-controlled study and a larger open-label study. The participant ages ranged from early childhood to adulthood in ReTRIACt, and from infancy to older adulthood in the open-label study. The report does not give the studies’ duration or detailed effect sizes, so those results cannot be compared more precisely from the supplied information.
“This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.”
— Hylton Joffe, MD, MMSc, of the FDA’s Center for Drug Evaluation and Research
Questions on Benefits and Safe Use
The source report does not provide study durations, detailed effect sizes or longer-term outcomes, and the two trials differed in design. The FDA-reported improvements concern hormone levels and cardiovascular or metabolic measures; the supplied material does not show whether treatment changes the course of neurological impairment or how durable the measured effects are.
Prescribing information warns of possible thyrotoxicosis and interference with laboratory tests that measure T3 levels. It also cautions against combining tiratricol with other thyroid medications. The supplied report does not detail how frequently these risks occurred in the trials or what monitoring schedule clinicians should use.
U.S. Launch Expected This Fall
Egetis Therapeutics said tiratricol is expected to become available in the United States within 8 to 10 weeks. The report does not specify an exact launch date, pricing, or access arrangements. Patients and clinicians will also need to consult the prescribing information for dosing and safety guidance, including the warnings about other thyroid medications, thyrotoxicosis and T3 laboratory testing.
Key Questions
What did the FDA approve tiratricol to treat?
The FDA approved tiratricol, marketed as Emcitate, for peripheral thyrotoxicosis in adults and children with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.
Is tiratricol the first FDA-approved treatment for MCT8 deficiency?
Yes. The FDA announcement described it as the first approval for the rare genetic disorder.
What evidence supported the approval?
The approval was supported by the randomized, placebo-controlled ReTRIACt study of 20 participants and an open-label study of 46 participants. The source report says tiratricol lowered excess blood thyroid hormone levels across both studies and improved some cardiovascular and metabolic measures affected by thyroid levels.
How is tiratricol taken, and what are common adverse effects?
It is taken once daily as a liquid suspension, orally or through a feeding tube. Reported common adverse effects include diarrhea, vomiting, rash and excessive sweating. Prescribing information also carries warnings, including that the drug is not intended for weight loss or obesity.
When will tiratricol be available in the United States?
Egetis Therapeutics said U.S. availability is expected within 8 to 10 weeks. The supplied report does not name a specific launch date.
Source: rss
Evergreen bestsellers Picks
bestsellers
As an affiliate, we earn on qualifying purchases.
